Pfizer Agrees to Settle 10,000 Zantac Lawsuits Over Alleged Cancer Risks, Bloomberg Reports
-- Pfizer has agreed to settle over 10,000 cases against its heartburn drug Zantac for allegedly hiding cancer-associated risks, Bloomberg reports, citing people familiar with the deal.
-- The agreements cover cases in state courts across the U.S., but don't completely resolve the company's exposure to Zantac claims, Bloomberg reports.
-- "Pfizer has explored and will continue to explore opportunistic settlements of certain cases if appropriate, and has settled certain cases," Pfizer said in a statement, according to Bloomberg. "The company has not sold a Zantac product in more than 15 years and did so only for a limited period of time."
-- Zantac has been owned by different drugmakers in its more than 30-year run as one of the most popular antacids in the U.S., Bloomberg reports.
Full article at https://www.bloomberg.com/news/articles/2024-05-08/pfizer-agrees-to-settle-more-than-10-000-zantac-cancer-lawsuits
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 08, 2024 13:47 ET (17:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now